Patient-related risk factors of infection and additional clinical information
CIED pocket thinning (mixed subgroup with co-existing another indication for TLE)
CIED pocket thinning (mixed subgroup with co-existing another indication for TLE)
Noninfective TLE indications
Noninfective TLE indications
Pocket infection with or without LRIE
Pocket infection with or without LRIE
Isolated LRIE (without pocket infection)
Isolated LRIE (without pocket infection)
P 1 vs 2 P 1 vs 3 P 1 vs 4
Number of patients / group number 60 1 2511 2 789 3 349 4
Form of results presentation (count/average; Sd/%) Count / average %/Sd Count / average %/Sd Count / average %/Sd Count / average %/Sd
Patient’s age during TLE Aver±Sd 68,95 12,56 64,77 16,38 69,51 13,23 66,38 14,27 0,05 0,45 0,19
Patient’s age during first system implantation Aver±Sd 62,00 13,10 55,93 17,98 61,87 14,14 68,61 15,65 0,01 0,94 <0,01
Sex (% of male patients) (%) n (%) 33 55,00% 1452 57,83% 564 71,48% 243 69,63% 0,64 <0,01 0,03
Underlaying heart disease: IHD, MI n (%) 35 58,33% 1410 56,15% 442 56,02% 177 50,72% 0,71 0,70 <0,01
NYHA III & IV n (%) 4 6,67% 354 14,10% 104 13,18% 99 28,37% 0,10 0,14 0,18
Congestive heart failure (symptomatic presently) n (%) 5 8,33% 488 19,43% 118 14,96% 84 24,07% 0,04 0,15 0,58
LVEF average (%) Aver±Sd 49,73 14,13% 49,99 15,46% 48,520 14,64% 47,37 15,45% 0,90 0,54 0,26
LVEF significantly limited / decreased / reduced (<30%) n (%) 7 11,67% 304 12,1% 104 13,18% 55 15,76% 0,90 0,71 0,41
Renal failure (any) n (%) 12 20,00% 465 18,52% 181 22,94% 133 38,11% 0,76 0,60 0,51
Diabetes (any) n (%) 7 11,67% 452 18,00% 179 22,69% 101 28,94% 0,21 0,05 0,81
Malignancy in history n (%) 4 6,67% 160 6,37% 48 6,08% 26 7,45% 0,91 0,84 0,17
Treatment with steroids in history n (%) 0 0,00% 29 1,15% 18 2,28% 15 4,30% 0,40 0,23 0,26
Permanent AF presence n (%) 12 20,00% 536 21,35% 206 26,11% 89 25,50% 0,80 0,27 0,05
Mechanical valve presence n (%) 1 1,67% 132 5,26% 35 4,44% 15 4,30% 0,21 0,28 0,88
Long-term anticoagulation was necessary n (%) 26 43,33% 982 39,11% 290 36,76% 146 41,83% 0,49 0,29 0,29
Long-term antiplatelet therapy in recent history n (%) 29 48,33% 1055 42,02% 342 43,35% 150 42,98% 0,31 0,46 <0,01
CHA2DS2–VASc scale - number of points Aver±Sd 3,20 0,01 2,90 1,73 3,19 1,67 3,17 1,75 0,18 0,96 0,90
HAS-BLED scale - number of points Aver±Sd 1,73 0,01 1,34 1,03 1,62 1,02 1,64 1,16 <0,01 <0,01 <0,01
Charlson’s co-morbidity index - number of points Aver±Sd 4,28 3,05 4,48 3,62 5,13 3,63 5,56 4,02 0,67 0,08 0,02
BMI Aver±Sd 27,65 4,66 27,95 5,74 27,72 3,87 27,65 4,48 0,69 0,08 1,00
CRP level Aver±Sd 15,56 34,90 10,67 24,65 29,09 43,45 75,40 77,84 0,13 0,02 <0,01
WBC (thousands) Aver±Sd 8,22 2,82 7,73 3,41 8,37 3,33 11,08 6,25 0,27 0,73 <0,01
Haemoglobin Aver±Sd 13,03 1,79 13,28 1,76 12,68 1,88 11,26 2,14 0,28 0,16 <0,01